PURPOSE: Immune-mediated diseases affect millions of people worldwide with an economic impact measured in the billions of dollars. Mesenchymal stem cells (MSCs) are being investigated in the treatment of certain immune mediated diseases, but their application in the treatment of the majority of these disorders remains largely unexplored. Keratoconjunctivitis sicca can occur as a result of progressive immune-mediated destruction of lacrimal tissue in dogs and humans, and immune-mediated joint disease is common to both species. In dogs, allogeneic MSC engraftment and migration have yet to be investigated in vivo in the context of repeated injections. METHODS: With these aims in mind, the engraftment of allogeneic canine MSCs after an injection into the periocular and intra-articular regions was followed in vivo using magnetic resonance and fluorescent imaging. RESULTS: The cells were shown to be resident near the site of the injection for a minimum of 2 weeks. Analysis of 61 tissues demonstrated preferential migration and subsequent engraftment of MSCs in the thymus as well as the gastrointestinal tract. These results also detail a novel in vivo imaging technique and demonstrate the differential spatial distribution of MSCs after migration away from the sites of local delivery. CONCLUSION: The active engraftment of the MSCs in combination with their previously documented immunomodulatory capabilities suggests the potential for therapeutic benefit in using MSCs for the treatment of periocular and joint diseases with immune involvement.
PURPOSE: Immune-mediated diseases affect millions of people worldwide with an economic impact measured in the billions of dollars. Mesenchymal stem cells (MSCs) are being investigated in the treatment of certain immune mediated diseases, but their application in the treatment of the majority of these disorders remains largely unexplored. Keratoconjunctivitis sicca can occur as a result of progressive immune-mediated destruction of lacrimal tissue in dogs and humans, and immune-mediated joint disease is common to both species. In dogs, allogeneic MSC engraftment and migration have yet to be investigated in vivo in the context of repeated injections. METHODS: With these aims in mind, the engraftment of allogeneic canine MSCs after an injection into the periocular and intra-articular regions was followed in vivo using magnetic resonance and fluorescent imaging. RESULTS: The cells were shown to be resident near the site of the injection for a minimum of 2 weeks. Analysis of 61 tissues demonstrated preferential migration and subsequent engraftment of MSCs in the thymus as well as the gastrointestinal tract. These results also detail a novel in vivo imaging technique and demonstrate the differential spatial distribution of MSCs after migration away from the sites of local delivery. CONCLUSION: The active engraftment of the MSCs in combination with their previously documented immunomodulatory capabilities suggests the potential for therapeutic benefit in using MSCs for the treatment of periocular and joint diseases with immune involvement.
Authors: P Richard Vulliet; Melanie Greeley; S Mitchell Halloran; Kristin A MacDonald; Mark D Kittleson Journal: Lancet Date: 2004-03-06 Impact factor: 79.321
Authors: Joshua A Wood; Irene Ly; Dori L Borjesson; Paul F Nealey; Paul Russell; Christopher J Murphy Journal: Exp Cell Res Date: 2012-07-04 Impact factor: 3.905
Authors: Joshua T Morgan; Heung Sun Kwon; Joshua A Wood; Dori L Borjesson; Stanislav I Tomarev; Christopher J Murphy; Paul Russell Journal: Exp Eye Res Date: 2015-02-24 Impact factor: 3.467
Authors: Sicilia T Grady; Lorraine Britton; Katrin Hinrichs; Alan J Nixon; Ashlee E Watts Journal: J Tissue Eng Regen Med Date: 2019-01-23 Impact factor: 3.963
Authors: Joshua T Morgan; Joshua A Wood; Naomi J Walker; Vijay Krishna Raghunathan; Dori L Borjesson; Christopher J Murphy; Paul Russell Journal: J Ocul Pharmacol Ther Date: 2014-01-23 Impact factor: 2.671
Authors: Maura K W Bittencourt; Michele A Barros; João Flávio P Martins; Jose Paulo C Vasconcellos; Bruna P Morais; Celine Pompeia; Matheus Domingues Bittencourt; Karine Dos Santos Evangelho; Irina Kerkis; Cristiane V Wenceslau Journal: Cell Med Date: 2016-10-18
Authors: Boaz Arzi; Amir Kol; Brian Murphy; Naomi J Walker; Joshua A Wood; Kaitlin Clark; Frank J M Verstraete; Dori L Borjesson Journal: Stem Cells Dev Date: 2014-12-31 Impact factor: 3.272
Authors: Amir Kol; Soraya Foutouhi; Naomi J Walker; Nguyet T Kong; Bart C Weimer; Dori L Borjesson Journal: Stem Cells Dev Date: 2014-06-26 Impact factor: 3.272
Authors: Antonio J Villatoro; Viviana Fernández; Silvia Claros; Gustavo A Rico-Llanos; José Becerra; José A Andrades Journal: Biomed Res Int Date: 2015-02-23 Impact factor: 3.411